8-K
filed June 18, 2026, 4:05 PM ET
ticker GPCR
CIK 0001888886
other
confidence high
sentiment neutral
materiality 0.10
Structure Therapeutics shareholders elect directors, ratify auditor, approve say-on-pay at 2026 AGM
Structure Therapeutics Inc.
- Elected Ted W. Love, Raymond Stevens, Daniel G. Welch as Class III directors with >161M votes for each.
- Ratified Ernst & Young as independent auditor for FY2026: 164.8M for, 20.8K against.
- Advisory vote on executive compensation approved: 158.5M for, 6.2M against, 212.7K abstentions.
- 213.2M ordinary shares outstanding as of record date April 20, 2026.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Structure Therapeutics Inc. shareholders approved Election of Directors at the 2026-06-17 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-17
Exact text from the filing
Proposal 1: Election of Directors Ted W. Love M.D., Raymond Stevens, Ph.D. and Daniel G. Welch were elected as a Class III directors, to hold office until the 2029 Annual General Meeting of Shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Structure Therapeutics Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-17 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-17
Exact text from the filing
Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s shareholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Structure Therapeutics Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2026-06-17 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-17
Exact text from the filing
Proposal 3: Advisory vote on the compensation of the Company’s named executive officers On an advisory basis, the shareholders approved the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual General Meeting.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.